HROHep03 Cells

HROHep03 is a human hepatocellular adenocarcinoma cell line established from the primary liver tumor of a 71-year-old Caucasian female patient within the HRO biobank series of patient-derived tumor cell lines developed by PD Dr. Michael Linnebacher since 2006. The tumor was classified as a primary adenocarcinoma at TNM stage T0NxMx, grade 3, reflecting a high-grade hepatic adenocarcinoma without confirmed distant metastasis at the time of tissue harvest. HROHep03 grows as an adherent monolayer with fibroblast-like morphology and was confirmed free of human pathogenic viruses HBV, HCV, and HIV, consistent with the stringent quality control standards of the Linnebacher biobank series.
HROHep03 is applicable in hepatocellular adenocarcinoma research, studies of high-grade liver tumor cell biology, drug sensitivity and resistance testing (sorafenib, cisplatin, 5-FU), liver tumor invasion and migration assays, and molecular pathway analysis. As part of the HRO biobank, this line provides a patient-specific biological resource that can be paired with matched immunological material from the same patient for personalized oncology research. Its fibroblast-like morphology distinguishes it phenotypically from the more common hepatocyte-like HCC lines and may reflect epithelial-to-mesenchymal features acquired during tumor progression or in vitro adaptation.